Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A new approach to gene therapy

Z Zhang1, M Eriksson, M Blombäck

  • 1Department of Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|June 2, 1998
PubMed
Summary

Chimeric RNA/DNA oligonucleotides offer a promising gene therapy for hemophilia by correcting specific DNA base pair mutations. This approach could potentially convert severe hemophilia phenotypes to milder ones by restoring functional clotting factor production.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fifth Åland Island conference on von Willebrand disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

An increased tendency in fibrinogen activity and its association with a hypo-fibrinolytic state in early stages after injury in patients without acute traumatic coagulopathy (ATC).

Journal of thrombosis and thrombolysis·2018
Same author

Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates.

Thrombosis and haemostasis·2013
Same author

Scientific visits to the Aland Islands.

Haemophilia : the official journal of the World Federation of Hemophilia·2013
Same author

von Willebrand disease biology.

Haemophilia : the official journal of the World Federation of Hemophilia·2012
Same author

Memories of my research into von Willebrand's disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2011

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Genetic Engineering

Background:

  • Gene therapy has long aimed to treat genetic disorders, but clinical success has been limited.
  • Traditional gene transfer methods using virus vectors have not yet yielded successful clinical trials.
  • Recent advancements include novel gene editing techniques for precise DNA modification.

Purpose of the Study:

  • To evaluate the potential of a novel mutation-repair method using chimeric RNA/DNA oligonucleotides for treating hemophilia A and B.
  • To assess the efficacy and safety of single basepair alteration for correcting coagulation factor gene mutations.
  • To explore the feasibility of converting severe hemophilia phenotypes to milder ones through gene repair.

Main Methods:

  • Utilized chimeric RNA/DNA oligonucleotides for targeted single basepair alteration in DNA.

Related Experiment Videos

  • Focused on well-characterized mutations in coagulation factor VIII (hemophilia A) and factor IX (hemophilia B) genes.
  • Assessed the repair efficacy and stability of gene expression in corrected cells.

    • Main Results:

    • The mutation-repair method demonstrated a single basepair replacement efficacy of up to 20%.
    • Repaired cells have the potential to produce normal clotting factors, leading to stable protein expression.
    • The approach aims to increase functional protein concentration, potentially ameliorating severe hemophilia phenotypes.

    Conclusions:

    • Chimeric RNA/DNA oligonucleotides represent a promising and safe gene therapy strategy for hemophilia.
    • The method's high replacement efficacy and safety profile suggest future clinical applicability.
    • Further research is needed as no correction has yet been observed for factor IX and von Willebrand factor gene mutations using this technique.